Abstract
BackgroundMalignant pleural mesothelioma (MPM) is an aggressive malignant tumor of mesothelial origin that shows a limited response to conventional chemotherapy and radiotherapy. Therefore, diagnosing MPM early is very important. Some researchers have previously reported that high-mobility group box 1 (HMGB1) was correlated with pulmonary fibrosis. MPM involves the malignant transformation of mesothelial cells, which originate from mesenchymal cells similar to lung fibroblasts. Here, we investigated serum levels of HMGB1 in patients with MPM and compared them with those of a population that had been exposed to asbestos without developing MPM.MethodsHMGB1 production from MPM cell lines was measured using ELISA. Serum HMGB1 levels were also examined in 61 MPM patients and 45 individuals with benign asbestos-related diseases.ResultsHMGB1 concentrations of 2 out of 4 MPM cell lines were higher than that of normal mesothelial cell line, Met-5A. We demonstrated that patients with MPM had significantly higher serum levels of HMGB1 than the population who had been exposed to asbestos but had not developed MPM. The difference in overall survival between groups with serum HMGB1 levels that were lower and higher than assumed cut-off values was significant.ConclusionsOur data suggest that serum HMGB1 concentration is a useful prognostic factor for MPM.
Highlights
Malignant pleural mesothelioma (MPM) is an aggressive malignant tumor of mesothelial origin, which shows a limited response to conventional chemotherapy and radiotherapy [1,2,3]
Evaluation of high-mobility group box 1 (HMGB1) production in mesothelioma and mesothelial cells We evaluated HMGB1 production in four mesothelioma cell lines and a mesothelial cell line by enzyme-linked immunosorbent assay (ELISA)
Serum levels of HMGB1 in patients with MPM, those with benign asbestos-related diseases, and healthy individuals with a history of asbestos exposure We recruited a total of 106 subjects with a history of asbestos exposure
Summary
Malignant pleural mesothelioma (MPM) is an aggressive malignant tumor of mesothelial origin that shows a limited response to conventional chemotherapy and radiotherapy. MPM involves the malignant transformation of mesothelial cells, which originate from mesenchymal cells similar to lung fibroblasts. We investigated serum levels of HMGB1 in patients with MPM and compared them with those of a population that had been exposed to asbestos without developing MPM. The multi-target antifolate pemetrexed was recently approved as a first-line agent in combination with cisplatin for the treatment of MPM, the overall survival of MPM patients remains very poor [4] with a median survival duration of 8–18 months [5]. Diagnosing MPM at an early stage is very important [1]. Efficient and practical serum biomarkers are required to aid the diagnosis of MPM Diagnosis by radiological and/ or histological examinations can often be very difficult.
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
